Podcast: Clearmind’s Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
Welcome to a new episode of our Benzinga Psychedelics Podcast. We are joined herein by executives of Clearmind Medicine (NASDAQ:CMND), a biotech company developing a proprietary, psychoactive yet non-hallucinogenic treatment for a diverse array of addictive behaviors, with Alcohol Use Disorder (aka AUD) as its first indication pursued.
In conversation with guests Dr. Adi Zuloff-Shani, Cleamind’s CEO, and Mark Haden, VP of business development and an addiction counseling and management specialist, we dive into the world of addiction treatment and what the intriguing molecule known as MEAI can do in different behavioral scenarios, including binge eating, metabolic disorders and cocaine addiction.
Listen to the full podcast on Spotify or wherever you get your podcasts.
Legal Path For Taking A Known Psychoactive Molecule To Consumers
The alcohol substitutes market is an interesting one. With virtually no competitors developing such therapeutic alternatives, the Clearmind team has taken up the 5-methoxy-2-aminoindane (or MEAI) molecule and built an active patent protection around treatment for several indications, starting with AUD.
First used in the 1990’s by alcohol …